MedTrace Logo

Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients

NCT01368419 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-04-24

No results posted yet for this study

Summary

This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Endostar

75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks

RADIATION

Radiotherapy

6～15MV X-ray, 2Gy/time，5times/week，6 weeks

Sponsors & Collaborators

  • The First People's Hospital of Lianyungang

    collaborator OTHER

  • Jiangsu Simcere Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaodong Jiang, MD · The First People's Hospital of Lianyungang

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01368419 on ClinicalTrials.gov